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Summary
PRINCIPLES: Neuroendocrine neoplasms (NENs) are be-
lieved to be associated with an increased risk for additional
malignancies (AMs). We aimed to (1) assess the occur-
rence of AM in NEN patients (2) investigate the character-
istics and temporal relationship of NEN patients with and
without AM.
METHODS: The SwissNET registry has prospectively
documented patients with NEN since 2008, covering the
entire area of Switzerland. Clinical characteristics, func-
tionality, location and histology of NEN as well as survival
of all consecutive patients were retrieved. The characterist-
ics of the AM (location, histology, time point of diagnosis
in relation to diagnosis of NEN) were extracted.
RESULTS: Out of 934 patients, 193 patients (21%) presen-
ted with AMs. There was no statistically significant dif-
ference with regard to location, functionality and grading
(G1–G3) between the NEN patients with and without AM.
AMs were diagnosed synchronously (±3 months), before
(>–3 months) and after (>+3 months) diagnosis of NEN
in 82 (42%), 96 (50%) and 13 (7%) patients, respectively.
Location of NEN correlated with the anatomical origin of
the AM. Age- and gender- corrected survival was not sig-
nificantly different between NEN patients with and without
AM.
CONCLUSION: The prevalence of AM in NEN is high.
The comparable characteristics with regard to functionality
and grading in the NEN cohorts with and without AM and
the similar location of AM and NEN suggest a selection
bias towards frequent imaging procedures in NEN patients
with AM.
Key words: NET; neuroendocrine tumour; secondary
malignancy; screening; survival
Introduction
Neuroendocrine neoplasms (NENs) are rare tumours with
an estimated annual incidence of 1–5 per 100 000, equally
affecting males and females [1, 2]. The median age at dia-
gnosis is approximately 63 years [2]. NENs represent a
highly heterogeneous group of tumours. Since neuroen-
docrine cells are distributed widely throughout the body,
NENs can be diagnosed in various organs, but are predom-
inantly found in the aerodigestive tract [3]. The most recent
nomenclature for neuroendocrine neoplasms of the digest-
ive system from the World Health Organization (WHO)
distinguishes two broad subgroups, according to the histo-
logical grade and differentiation: well-differentiated neur-
oendocrine tumours and poorly-differentiated neuroendo-
crine carcinomas [4].
NENs are believed to be associated with an increased risk
for additional malignancies (AMs). Previous studies re-
ported incidence rates between 7.1% and 46% for associ-
ated tumours [5, 6]. The wide range of incidence rates of
AM in different studies suggests a possible selection bi-
as. However, genetic predisposition, i.e. multiple endocrine
neoplasia (MEN) types 1 and 2 and von Hippel-Lindau
syndrome, endocrine effects of NEN, environmental influ-
ences or therapy modalities of NEN may also play a role
[7, 8].
We therefore aimed at assessing the clinical, functional
and histological characteristics of NEN patients with and
without AM. The primary site of the NEN and AM, and the
temporal relationship with NEN diagnosis were retrieved
in order to explore a potential relationship between the oc-
currence of NEN and AM. Furthermore, we investigated
the prevalence of AM in our cohort and the survival of
NEN patients with and without AM.
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Materials and methods
Study design and population
Since 2008, clinical data on Swiss patients with NENs has
been documented in a nation-wide prospective database,
the SwissNET registry [9]. Ethical approval was obtained
from the lead ethics committee in Bern and from all the
other cantonal ethics committees according to the Swiss
human research law of 2015 [10]. Currently, 45 participat-
ing hospitals across the whole of Switzerland are providing
SwissNET with the data of their consenting patients with
NEN, including about 50–60% of the expected incidence/
year in Switzerland.
Gatekeepers for the SwissNET registry are pathologists or
any medical doctors who report the diagnosis of NEN to
SwissNET. The patients are then contacted and written in-
formed consent is obtained, in which the patients agree to
the use of the encoded data for research purposes.
The inclusion criteria for the SwissNET registry comprises
all patients with NEN of the aerodigestive tract irrespective
of age based on the revised WHO criteria 2010 [11]. Pa-
tients with small cell neuroendocrine carcinoma of the lung
are excluded from the registry. All NENs, irrespective of
sporadic or genetic origin, are included.
Data of all consecutive patients recruited into the prospect-
ive SwissNET registry between 2008 and 2015 were in-
cluded. AM was defined as at least one additional malig-
nant neoplasm. Clinical characteristics, functionality, loc-
ation and histology of NEN, as well as survival of all pa-
tients were retrieved. The characteristics of AMs (location,
histology, time-point of diagnosis in relation to diagnos-
is of NEN) were extracted. Synchronous AM was defined
as occurrence of an AM within the range of 3 months be-
fore until 3 months after the diagnosis of NEN. Metachron-
ous diagnoses of AM before and after NEN diagnosis were
defined as >3 months before or after NEN diagnosis, re-
spectively. The characteristics of NEN patients with AM
were compared with NEN patients without AM.
Statistical analysis
Categorical variables are reported as number and percent-
age in each category and compared between groups with
Fisher’s exact tests. Continuous data are reported as medi-
an and interquartile range (IQR) and compared with Wil-
coxon rank-sum tests.
Survival analysis was performed with Kaplan-Meier curves
and Cox proportional hazard models. Patients became at
risk at the date of NEN diagnosis and death was considered
as an event. Follow-up time was restricted to three years.
Cox models were fitted with additional malignancies as the
only covariate and adjusted for sex and age (the latter with
a linear time-dependent effect). The proportional hazard as-
sumption was checked by log-log plots and the analysis
of Schoenfeld residuals. All analyses were done in Stata
Release 13 (Ref: StataCorp. 2013. Stata Statistical Soft-
ware: Release 13. College Station, TX: StataCorp LP).
Results
SwissNET cohort
The Swiss Neuroendocrine Tumour registry comprised 934
patients between 2008 and 2015. Patients were followed up
for a median time of 1.49 years (IQR 0.28 to 3.13) (table
1). Patient’s and tumour characteristics are summarised in
tables 1 and 2. A total of 113 patients (12%) suffered from
secreting NENs. Carcinoid syndrome was the most com-
mon registered syndrome (40 patients; 4%). The most com-
mon primary site was the ileum (205 tumours; 22%) fol-
lowed by the pancreas (201 tumours, 22%), the appendix/
caecum (165 tumours; 18%) and lung (138 tumours; 15%).
In 57 patients (6%), the anatomical origin of the NEN
could not be established (cancer of unknown primary;
CUP). In total, in 14 patients a syndromic disease was doc-
umented, seven patients with MEN syndrome, one patient
with tuberous sclerosis, one patient with neurofibromatosis
type 1 and five patients with von Hippel-Lindau disease.
NEN patients without AM
A total of 741 patients (79%) experienced no AM during
the observation period. The median follow-up time was
1.49 years (IQR 0.27 to 3.14) (table 1). Patient and tumour
characteristics are provided in tables 1 and 2. In total, 92
cases (12%) were recorded to be hormonally active. Car-
cinoid syndrome represented the most common secretory
NENs (33 patients; 4%). The most common primary NEN
sites were the pancreas and small intestine (157 cases; 21%
each), followed by appendix/caecum (128 cases; 17%) and
lung tumours (117 cases, 16%).
NEN patients with AM
One hundred and ninety-three patients (21%) were dia-
gnosed with at least one AM. The median age at diagnosis
was 67 years. The median follow up time was 1.49 years
(IQR 0.27 to 3.14) (table 1). Patient and tumour charac-
teristics are presented in tables 1 and 2. A secreting NEN
was documented in 21 patients (11%). Carcinoid syndrome
was the most prevalent syndrome (7 patients; 4%). The
most common primary site of NEN was the ileum (48 tu-
mours, 25%). NEN of pancreatic, appendicular/caecal and
pulmonary origin occurred less often: 44 tumours, 23%; 35
tumours, 18%; 21 tumours, 11%, respectively (table 2)
Table 1: Demographics for patients with and without additional malignancies.
All patients in registry Patients with AM Patients without AM p value
n = 934 n = 193 n = 741 0.288
Age at diagnosis (yr), median (IQR) 62.2 (49.8–71.6) 67.0 (60.1–73.7) 60.2 (47.9–70.5) <0.001
Sex – male, n (%) 501 (54%) 101 (52%) 400 (54%) 0.686
Follow-up (yr), median (IQR) 1.49 (0.28–3.13) 1.49 (0.29–3.12) 1.49 (0.27–3.14) 0.990
Deceased, n (%) 173 (19%) 53 (27%) 120 (16%) <0.001
AM = additional malignancy; IQR = interquartile range
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Comparison between the cohorts of NEN patients
without and with AM
The quality of data with regard to grading and functionality
was not significantly different between the cohorts with
and without AM. Primary site, NEN grading, functionality
and the median follow-up time were not statistically differ-
ent between the patients with and without AM (tables 1 and
2). The median age of the patients with AM at diagnosis
of NEN was 67 years, significantly older than the cohort
without AM (p <0.001).
Location of AM in relation to primary site of NEN
Patients with an AM of the gastrointestinal tract (67 pa-
tients) had their NEN mainly located in the gastrointestinal
tract (49 patients, 73%), whereas patients with an AM of
the lung (14 patients) had primarily a NEN of the lung (6
patients, 43%). AM of the urogenital tract was often as-
sociated with pancreatic and ileal NEN (33 patients, 69%)
(table 3).
Time-point of diagnosis of AM in relation to the
diagnosis of NEN
A synchronous diagnosis of the AM and the NEN could
be documented in almost half of the AM cohort (82 pa-
tients; 42%) (table 4). Appendicular NEN accounted for
the highest proportion of synchronously detected NENs (28
out of 82 patients, 34%). Small bowel and pancreatic NEN
represented 20% (16 patients) and 18% (15 patients), re-
spectively of all simultaneously diagnosed NENs. In con-
trast, diagnosis of NEN of the appendix was associated in
76% with synchronous diagnosis of an AM (table 5).
The remaining AMs were diagnosed metachronously. Most
of the AMs were detected before the onset of the NEN
(50%) and a minority of cases afterwards (7%). The time
intervals for a diagnosis of AM prior and after the NEN
diagnosis were –4.7 (IQR –8.5 to –1.1) and +1.8 (IQR 0.9
to 4.4) years, respectively (table 4).
Patients with metachronously diagnosed AM before the
diagnoses of the NEN had their NEN most often in the
small bowel and in the pancreas (27 out of 96 patients; 28%
each) and in the lung (12 patients, 13%). In contrast, a NEN
of pancreatic origin was often diagnosed during follow-up
of urogenital AMs, and lung NENs after lung and breast
carcinomas.
Patients with an AM diagnosed after the onset of the NEN
had their primary tumour located in the small bowel (4 out
of 13; 31%), stomach (3; 23%), or pancreas (2; 15%) (table
5).
Prevalence data
The prevalence for all AM sites including all patients of
the SwissNET registry was 21.2% and 20.2% for women
Table 2: Clinical characteristics of neuroendocrine neoplasms for patients with and without additional malignancies.
All patients in registry Patients with AM Patients without AM p value
n = 934 n = 193 n = 741
Site of NEN
Foregut 429 (46%) 86 (45%) 343 (46%)
Lung 138 (15%) 21 (11%) 117 (16%)
Pancreas 201 (22%) 44 (23%) 157 (21%)
Others 90 (10%) 21 (11%) 69 (9%)
Midgut 373 (40%) 85 (44%) 288 (39%)
Ileum 205 (22%) 48 (25%) 157 (21%)
Appendix/caecum 165 (18%) 37 (19%) 128 (17%)
Others 3 (0%) 0 (0%) 3 (0%)
Hindgut 56 (6%) 6 (3%) 50 (7%)
CUP 57 (6%) 11 (6%) 46 (6%)
Others 16 (2%) 4 (2%) 12 (2%)
Unknown 3 (0%) 1 (1%) 2 (0%)
Histological grading* 0.419
G1 506 (54%) 108 (56%) 398 (54%)
G2 205 (22%) 37 (19%) 168 (23%)
G3 108 (12%) 18 (9%) 90 (12%)
Unknown 115 (12%) 30 (16%) 85 (11%)
Functional tumour 0.454
No 575 (62%) 129 (67%) 446 (60%)
Yes 113 (12%) 21 (11%) 92 (12%)
Carcinoid 40 (4%) 7 (4%) 33 (4%)
Cushing 2 (0%) 1 (1%) 1 (0%)
Gastrinoma 14 (1%) 3 (2%) 11 (1%)
Glucagonoma 5 (1%) 3 (2%) 2 (0%)
Insulinoma 32 (3%) 4 (2%) 28 (4%)
Somatostatinoma 3 (0%) 1 (1%) 2 (0%)
VIPoma 4 (0%) 0 (0%) 4 (1%)
Unknown 13 (1%) 2 (1%) 11 (1%)
Unknown 246 (26%) 43 (22%) 203 (27%)
AM = additional malignancy; CUP = cancer of unknown primary; NEN = neuroendocrine neoplasm; VIP = vasoactive intestinal peptide
* According to WHO classification criteria 2010
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and men, respectively (supplementary table S1 in the ap-
pendix). The prevalences for the assessed subtypes are also
documented in table S1.
Survival analysis
Follow-up data for survival analysis was available for 844
of 934 patients (90%). The cumulative overall risk for
death of NEN patients was significantly increased in the
cohort with AM in the crude model (hazard ratio [HR]
1.63, 95% confidence interval [CI] 1.13 to 2.35, p = 0.009).
Forty-six patients (26%) and 110 patients (16%) died in the
patient cohorts with and without AM, respectively. When
adjusted for age and gender, however, statistical signific-
ance was lost (HR = 1.18, 95% CI 0.81 to 1.70, p = 0.389)
(data not shown).
Discussion
The main findings of this study can be summarised as fol-
lows: (1) AMs were diagnosed in 21% of the patients with
NEN; (2) the location of the primary site, grading and func-
tionality were not significantly different in NEN patients
with or without AM; (3) the type of AM covered a broad
spectrum of neoplasms, but were mainly associated with
NEN in a similar anatomical context and were primarily
diagnosed before or synchronously with the diagnosis of
NEN.
In our cohort 21% of the NEN patients suffered from an
AM consistent with previously reported data in the literat-
ure [12, 13]. The characteristics of the AM in NEN patients
covered a broad spectrum of neoplasms without any pre-
dilections consistent with previous data [5, 14].
Table 3: Relation between the primary site of neuroendocrine malignancy and first additional malignancy.
Site of AM
Gastrointestinal
tract
Urogenital tract Breast Lung Lymphoma Others
Site of NEN n = 67 n = 48 n = 22 n = 14 n = 6 n = 36
Foregut 25 (37%) 19 (40%) 11 (50%) 11 (79%) 2 (33%) 18 (50%)
Lung 1 (1%) – 6 (27%) 6 (43%) 1 (17%) 7 (19%)
Pancreas 14 (21%) 18 (38%) 3 (14%) 2 (14%) 1 (17%) 6 (17%)
Others 10 (15%) 1 (2%) 2 (9%) 3 (21%) – 5 (14%)
Midgut 37 (55%) 23 (48%) 7 (32%) 3 (21%) 3 (50%) 12 (33%)
Ileum 14 (21%) 15 (31%) 5 (23%) 3 (21%) 3 (50%) 8 (22%)
Appendix/caecum 23 (34%) 8 (17%) 2 (9%) – – 4 (11%)
Hindgut 2 (3%) 2 (4%) 1 (5%) – – 1 (3%)
CUP 1 (1%) 3 (6%) 2 (9%) – 1 (17%) 4 (11%)
Others 2 (3%) 1 (2%) – – – 1 (3%)
Unknown – – 1 (5%) – – –
AM = additional malignancy; CUP = cancer of unknown primary; NEN = neuroendocrine neoplasm
Table 4: Temporal relation between neuroendocrine neoplasm and the first additional malignancy.
Temporal relationship of NEN and AM n = 193
Metachronous, before NEN 96 (50%)
Synchronous 82 (42%)
Metachronous, after NEN 13 (7%)
Unknown 2 (1%)
Time between NEN and AM, synchronous (yr) n = 81, 0.0 (–0.0 to 0.0)
Time between NEN and AM, before (yr) n = 94, –4.7 (–8.5 to –1.1)
Time between NEN and AM, after (yr) n = 13, 1.8 (0.9 to 4.4)
AM = additional malignancy; NEN = neuroendocrine neoplasm
Time interval was not registered for 5 patients (1 with synchronous, 2 with metachronous and 2 with unknown relation).
Table 5: Site of neuroendocrine neoplasm and timing of first additional malignancy.
Timing of first AM
Site of NEN Metachronous, before NEN Synchronous Metachronous, after NEN
Foregut (n = 86) 47 (55%) 31 (36%) 8 (9%)
Lung (n = 21) 12 (57%) 8 (38%) 1 (5%)
Pancreas (n = 44) 27 (61%) 15 (34%) 2 (5%)
Others (n = 21) 8 (38%) 8 (38%) 5 (24%)
Midgut (n = 84) 36 (43%) 44 (52%) 4 (5%)
Ileum (n = 47) 27 (57%) 16 (34%) 4 (9%)
Appendix/caecum (n = 37) 9 (24%) 28 (76%) –
Hindgut (n = 6) 5 (83%) 1 (17%) –
CUP (n = 10) 6 (60%) 4 (40%) –
Others (n = 4) 1 (25%) 2 (50%) 1 (25%)
Unknown (n = 1) 1 (100%) – –
AM = additional malignancy; CUP = cancer of unknown primary; NEN = neuroendocrine neoplasm
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Location of primary site and grading of NEN were not sig-
nificantly different in patients with and without AM. This
indicates that the association is related rather to chance than
to a specific – possible biologically explained – pattern.
Additionally, the characteristics of functional NEN were
similar in the cohort with AM compared with the cohort
without AM. Although this suggests that the metabolites
secreted by the NEN probably do not play an important
biological role in the context of the occurrence of AM, no
definitive conclusion can be drawn owing to the limited pa-
tient numbers and highly heterogeneous patient population.
Interestingly, NEN of the gastrointestinal tract were mainly
associated with AM of the gastrointestinal tract, and pa-
tients with lung NEN had mainly an AM of the lung. This
finding is consistent with the hypothesis that the investiga-
tion of a possible neoplasm in a given clinical context may
have resulted in the detection of two different tumour entit-
ies in the similar anatomical context using the correspond-
ing diagnostic modalities (imaging, endoscopies) [15, 16].
Most of the AMs were diagnosed before or simultaneously
with the NEN. The rate of AM diagnosis is approximately
the same in the two time periods “metachronously before”
and “synchronously”. Our results may, firstly, indicate that
the investigations for a neoplasm (other than NEN) resulted
in the additional diagnosis of NEN and, therefore, ques-
tions the sequence of diagnosis between NEN and AM. The
awareness that more than 50% of the NEN in our cohort
are well differentiated (NEN G1) and, therefore, character-
ised by a slow growth rate and long asymptomatic period
supports the hypothesis of screening bias. Secondly, detec-
tion bias could explain the increased occurrence of syn-
chronously diagnosed AM and NEN. Notably, the screen-
ing methods and their frequency were in accordance with
local practice and are not documented in the registry. The
occurrence of AM after NEN diagnosis was significantly
less. Most likely, the short follow-up explains this finding.
The association of NEN and AM in the same anatomical
context – as mentioned before – is in line with this hypo-
thesis. However, the numbers are small. In the biggest re-
ported cohort from the Netherlands 67 AM (13,7%) in 459
NEN patients have been diagnosed, 13 (19%), 25 (37%)
and 29 (44%), synchronously, metachronously before and
after NEN diagnosis, respectively [15]. In the publication
of Krausch et al., notable for a much longer follow-up
time but with a small sample size (n = 143), similar data
were presented, reporting mostly metachronous AMs be-
fore NEN diagnosis (8/11 patients) [17].
Whether there is a true rise in incidence of additional ma-
lignancies when compared with the corresponding malig-
nancy in the general population is still an unanswered is-
sue. In a retrospective analysis from Krausch et al., second-
ary malignancies, especially with gastroenteropancreatic
NENs, are reported to be more frequent than in the gen-
eral population [17]. Since only in a few patients (n = 13)
an AM was diagnosed after the diagnosis of NEN, and be-
cause of the relatively short follow-up, the calculation of a
valid incidence rate is not possible. However, the prevalen-
ce of AM in our study with regard to all cancer sites was
approximately 20%, which appears to be increased com-
pared with the reported prevalence of 3.6% for all cancer
sites in Switzerland (National Institute for Cancer Epidemi-
ology and Registration; NICER) [18]. Splitting the AM ac-
cording to their specific origin left only a small number of
patients per group, thereby hampering a meaningful com-
parison with the NICER data (table S1).
Although the crude analysis of survival suggested a sig-
nificant increase in all-cause mortality in the cohort with
AM, adjustment for age and gender did not confirm this.
Thus, it is probably rather age (and possibly gender) that
relevantly impact on the increased mortality rate than the
AM per se. The fact that the cohort of patients with NEN
and AM is significantly older is consistent with this hypo-
thesis. This result is consistent with previous data in two
small series of patients with NEN. Krausch and colleagues
reported a subtle separation of the survival curves without
statistical significance (p = 0.349) [17]. The findings of
Prommegger et al. indicate that there was no survival dif-
ference between patients with and without AM [19].
The strength of our study is based on the high patient num-
bers included in the analysis and the high quality of data
assessment within the prospective SwissNET registry. The
observational nature of the data and the relatively short
follow-up time may influence and limit the interpretation
of the results.
In conclusion, the current data indicate that the suggested
increase in AM in NEN patients is related rather to the in-
creased rate of investigational procedures in a given clin-
ical context than to a true biological association. Based
on the present results, specific investigations aimed at dia-
gnosing AM are probably not mandatory, but clearly more
evidence with regard to this issue is needed.
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Appendix: Supplementary table
Table S1: Prevalence of additional malignancies in all patients in the SwissNET registry.
Women
(n = 433)
Men
(n = 501)
n (%)
All sites 92 (21.2%) 101 (20.2%)
Gastrointestinal 28 (6.5%) 39 (7.8%)
Male genital tract 0 (0.0%) 24 (4.8%)
Breast 22 (5.1%) 0 (0.0%)
Female genital tract 8 (1.8%) 0 (0.0%)
Lung 6 (1.4%) 8 (1.6%)
Lymphoma 4 (0.9%) 2 (0.4%)
Kidney 1 (0.2%) 7 (1.4%)
Bladder 1 (0.2%) 7 (1.4%)
Other 22 (5.1%) 14 (2.8%)
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